Physician
Candel, Alvaro
Candel, Alvaro was paid $6.40M by Medicaid between Jan 2018 and Dec 2024, across 193 billing codes. Its largest line is 87389, Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies — 6.8% of everything it billed.
33Billing provider infoCANDEL, ALVARO
ELMHURST, IL 60126
ELMHURST, IL 60126
33aNPI1528019189assigned 05/16/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$6.40M
24GClaims933,963
24DCodes billed193
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#6 of 398
Median peer was paid$66K
This provider vs. median97×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,725 | $556K | |
| 2019 | 117,419 | $723K | |
| 2020 | 122,265 | $759K | |
| 2021 | 132,116 | $1.11M | |
| 2022 | 138,879 | $1.06M | |
| 2023 | 166,221 | $1.23M | |
| 2024incomplete | 165,338 | $970K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 6.8% | 9,029 | 8,652 | $438K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 6.0% | 7,160 | 6,139 | $383K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.7% | 10,605 | 9,106 | $367K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 5.4% | 4,559 | 4,405 | $344K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.1% | 15,131 | 14,157 | $328K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.1% | 15,004 | 14,072 | $325K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.0% | 112,543 | 78,286 | $320K |
| 80053 | Comprehensive metabolic panel | 4.2% | 52,140 | 43,407 | $266K |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.0% | 62,618 | 39,796 | $257K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.4% | 26,949 | 25,760 | $218K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.4% | 915 | 728 | $152K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 6,195 | 5,424 | $148K |
181 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 22,775 | $113K |
| 80061 | Lipid panel | 1.5% | 26,479 | $96K |
| 86780 | 1.3% | 9,912 | $81K | |
| 87631 | 1.2% | 1,459 | $75K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.1% | 5,330 | $72K |
| 87430 | 1.0% | 8,576 | $67K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 1,864 | $67K |
| 83735 | 1.0% | 19,184 | $66K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,116 | $64K |
| 81025 | <1% | 26,274 | $58K | |
| 84484 | <1% | 13,336 | $57K | |
| 85027 | <1% | 19,924 | $57K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,559 | $55K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,421 | $53K |
| 87040 | <1% | 4,486 | $51K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,402 | $51K |
| 87808 | <1% | 6,520 | $51K | |
| 87081 | <1% | 17,339 | $50K | |
| 86480 | <1% | 1,899 | $49K | |
| 87641 | <1% | 2,212 | $49K | |
| 80076 | <1% | 13,371 | $47K | |
| 82962 | <1% | 25,095 | $45K | |
| 86803 | <1% | 5,461 | $44K | |
| 81001 | <1% | 30,808 | $44K | |
| 87653 | <1% | 1,913 | $42K | |
| 83690 | <1% | 12,158 | $41K | |
| 87186 | <1% | 6,870 | $40K | |
| 82607 | <1% | 6,593 | $39K | |
| 84439 | <1% | 8,974 | $39K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,665 | $38K |
| 83880 | <1% | 3,398 | $35K | |
| 87340 | <1% | 5,352 | $34K | |
| 86850 | <1% | 11,577 | $34K | |
| 83520 | <1% | 2,697 | $33K | |
| 82805 | <1% | 1,239 | $32K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,264 | $31K |
| 86901 | <1% | 13,720 | $31K | |
| 87493 | <1% | 1,395 | $30K | |
| 82728 | <1% | 6,354 | $25K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 846 | $25K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,058 | $24K |
| 84466 | <1% | 5,680 | $24K | |
| 85379 | <1% | 6,403 | $24K | |
| 86900 | <1% | 13,720 | $23K | |
| 86003 | <1% | 800 | $22K | |
| 87486 | <1% | 915 | $20K | |
| 87581 | <1% | 914 | $20K | |
| 83605 | <1% | 3,590 | $20K | |
| 82261 | <1% | 2,423 | $20K | |
| 83655 | <1% | 3,184 | $19K | |
| 83540 | <1% | 5,821 | $18K | |
| 87205 | <1% | 9,922 | $18K | |
| 82570 | <1% | 7,589 | $17K | |
| 85730 | <1% | 4,760 | $17K | |
| 83498 | <1% | 2,556 | $17K | |
| 86038 | <1% | 2,160 | $16K | |
| 85610 | <1% | 8,519 | $16K | |
| 86140 | <1% | 6,727 | $16K | |
| 84702 | <1% | 3,592 | $15K | |
| 84100 | <1% | 6,713 | $14K | |
| 83013 | <1% | 635 | $14K | |
| 81003 | <1% | 12,394 | $13K | |
| 81514 | <1% | 226 | $13K | |
| 86762 | <1% | 3,072 | $13K | |
| 84403 | <1% | 1,036 | $13K | |
| 80069 | <1% | 2,960 | $12K | |
| 86706 | <1% | 1,782 | $12K | |
| 87088 | <1% | 2,128 | $11K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,242 | $11K |
| 82043 | <1% | 5,492 | $11K | |
| 87507 | <1% | 159 | $10K | |
| 84481 | <1% | 2,067 | $10K | |
| 82016 | <1% | 2,427 | $10K | |
| 82247 | <1% | 3,942 | $10K | |
| 87070 | <1% | 2,920 | $9K | |
| 84410 | <1% | 406 | $9K | |
| 86704 | <1% | 1,178 | $9K | |
| 82248 | <1% | 4,164 | $9K | |
| 82128 | <1% | 2,423 | $8K | |
| 82784 | <1% | 1,229 | $8K | |
| 83970 | <1% | 539 | $8K | |
| 83001 | <1% | 917 | $8K | |
| 85652 | <1% | 5,956 | $8K | |
| 82746 | <1% | 1,362 | $8K | |
| 82776 | <1% | 2,427 | $8K | |
| 85007 | <1% | 4,295 | $7K | |
| 82950 | <1% | 3,180 | $7K | |
| 82760 | <1% | 2,426 | $7K | |
| 86225 | <1% | 1,214 | $7K | |
| 82550 | <1% | 2,623 | $7K | |
| 84153 | <1% | 1,148 | $7K | |
| 82565 | <1% | 2,862 | $6K | |
| 84030 | <1% | 2,457 | $6K | |
| 84132 | <1% | 3,258 | $6K | |
| 83020 | <1% | 1,411 | $6K | |
| 84703 | <1% | 1,640 | $6K | |
| 83516 | <1% | 802 | $6K | |
| 84450 | <1% | 2,346 | $6K | |
| 86431 | <1% | 1,502 | $5K | |
| 84460 | <1% | 2,118 | $5K | |
| 82785 | <1% | 1,056 | $5K | |
| 84402 | <1% | 563 | $5K | |
| 82951 | <1% | 804 | $5K | |
| 86787 | <1% | 680 | $5K | |
| 86235 | <1% | 238 | $5K | |
| 84146 | <1% | 648 | $4K | |
| 85018 | <1% | 3,562 | $4K | |
| 80047 | <1% | 866 | $4K | |
| 83615 | <1% | 1,400 | $4K | |
| 86200 | <1% | 648 | $3K | |
| 81002 | <1% | 2,691 | $3K | |
| 86920 | <1% | 845 | $3K | |
| 82105 | <1% | 379 | $3K | |
| 83525 | <1% | 643 | $3K | |
| 85014 | <1% | 2,506 | $3K | |
| 86880 | <1% | 953 | $3K | |
| 82670 | <1% | 302 | $3K | |
| 87147 | <1% | 1,543 | $3K | |
| 83002 | <1% | 445 | $3K | |
| 84156 | <1% | 2,237 | $3K | |
| 86708 | <1% | 501 | $2K | |
| 82627 | <1% | 333 | $2K | |
| 84144 | <1% | 300 | $2K | |
| 82533 | <1% | 291 | $2K | |
| 83021 | <1% | 323 | $2K | |
| 80202 | <1% | 251 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 70 | $2K |
| 87077 | <1% | 946 | $2K | |
| 88307 | <1% | 21 | $2K | |
| 87075 | <1% | 240 | $2K | |
| 84550 | <1% | 715 | $1K | |
| 86376 | <1% | 318 | $1K | |
| 86160 | <1% | 143 | $1K | |
| 82952 | <1% | 626 | $1K | |
| 86039 | <1% | 221 | $1K | |
| 86800 | <1% | 186 | $1K | |
| 86769 | <1% | 54 | $1K | |
| 82274 | <1% | 187 | $950.96 | |
| 87045 | <1% | 162 | $947.25 | |
| 82077 | <1% | 88 | $911.68 | |
| 87427 | <1% | 122 | $748.71 | |
| 86077 | <1% | 22 | $707.40 | |
| 87106 | <1% | 965 | $601.75 | |
| 86709 | <1% | 152 | $561.36 | |
| 86334 | <1% | 40 | $558.00 | |
| 85045 | <1% | 425 | $535.24 | |
| 87529 | <1% | 12 | $503.80 | |
| 82803 | <1% | 31 | $484.84 | |
| 87046 | <1% | 162 | $460.76 | |
| 84145 | <1% | 84 | $457.90 | |
| 86735 | <1% | 66 | $419.10 | |
| 88312 | <1% | 13 | $392.57 | |
| 86765 | <1% | 87 | $367.36 | |
| 82040 | <1% | 164 | $345.03 | |
| 87338 | <1% | 39 | $340.08 | |
| 86308 | <1% | 142 | $326.40 | |
| 84425 | <1% | 47 | $318.52 | |
| 81015 | <1% | 237 | $301.30 | |
| 87272 | <1% | 36 | $260.28 | |
| 82330 | <1% | 32 | $247.16 | |
| 82150 | <1% | 74 | $235.42 | |
| 87660 | <1% | 25 | $210.00 | |
| 87329 | <1% | 36 | $180.72 | |
| 87480 | <1% | 12 | $157.20 | |
| 87510 | <1% | 12 | $157.20 | |
| 86701 | <1% | 35 | $149.04 | |
| 83721 | <1% | 37 | $140.10 | |
| 80050 | General health panel | <1% | 151 | $138.45 |
| 84480 | <1% | 30 | $137.24 | |
| 86870 | <1% | 20 | $136.23 | |
| 86255 | <1% | 17 | $112.22 | |
| 83550 | <1% | 27 | $108.41 | |
| 85384 | <1% | 39 | $108.05 | |
| 84300 | <1% | 47 | $101.76 | |
| 82140 | <1% | 23 | $82.34 | |
| 82272 | <1% | 55 | $67.60 | |
| 87015 | <1% | 14 | $46.76 | |
| 82947 | <1% | 26 | $34.71 | |
| 84295 | <1% | 15 | $33.56 | |
| 80320 | 0% | 313 | $0.00 | |
| 80329 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.